WO2009001661A1 - アルツハイマー病の予防又は治療のための医薬 - Google Patents
アルツハイマー病の予防又は治療のための医薬 Download PDFInfo
- Publication number
- WO2009001661A1 WO2009001661A1 PCT/JP2008/060513 JP2008060513W WO2009001661A1 WO 2009001661 A1 WO2009001661 A1 WO 2009001661A1 JP 2008060513 W JP2008060513 W JP 2008060513W WO 2009001661 A1 WO2009001661 A1 WO 2009001661A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alzheimer
- disease
- prevention
- treatment
- medicinal agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009520426A JP5311413B2 (ja) | 2007-06-22 | 2008-06-09 | アルツハイマー病の予防又は治療のための医薬 |
US12/452,198 US20100130567A1 (en) | 2007-06-22 | 2008-06-09 | Medical agent for prevention or treatment of alzheimer 's disease |
EP08765314.3A EP2174666B1 (en) | 2007-06-22 | 2008-06-09 | Medicinal agent for treatment of amyloid beta-induced cerebral circulation or cerebral blood flow disorders |
ES08765314.3T ES2446296T3 (es) | 2007-06-22 | 2008-06-09 | Agente medicinal para el tratamiento de trastornos de la circulación cerebral o del flujo sanguíneo cerebral inducidos por beta amiloide |
TW097121836A TWI441634B (zh) | 2007-06-22 | 2008-06-12 | 4-(1-羥基-1-甲基乙基)-2-丙基-1-〔4-〔2-(四唑-5-基)苯基〕苯基〕甲基咪唑-5-羧酸、其藥理容許鹽或其藥理容許酯之用途 |
US13/489,580 US20120302614A1 (en) | 2007-06-22 | 2012-06-06 | Method for improving cerebral circulation or treating a cerebral blood flow disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-165071 | 2007-06-22 | ||
JP2007165071 | 2007-06-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/489,580 Division US20120302614A1 (en) | 2007-06-22 | 2012-06-06 | Method for improving cerebral circulation or treating a cerebral blood flow disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009001661A1 true WO2009001661A1 (ja) | 2008-12-31 |
Family
ID=40185482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/060513 WO2009001661A1 (ja) | 2007-06-22 | 2008-06-09 | アルツハイマー病の予防又は治療のための医薬 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20100130567A1 (ja) |
EP (1) | EP2174666B1 (ja) |
JP (1) | JP5311413B2 (ja) |
ES (1) | ES2446296T3 (ja) |
TW (1) | TWI441634B (ja) |
WO (1) | WO2009001661A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101062907B1 (ko) | 2009-10-20 | 2011-09-06 | 주식회사 씨티씨바이오 | 올메사탄 실렉세틸을 포함하는 고혈압 치료용 약학 조성물 |
KR101062908B1 (ko) | 2009-10-27 | 2011-09-06 | 주식회사 씨티씨바이오 | 올메사탄 유도체를 포함하는 고혈압 치료용 약학 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0578328A (ja) * | 1991-02-21 | 1993-03-30 | Sankyo Co Ltd | ビフエニルメチルイミダゾール誘導体 |
WO2007112288A2 (en) * | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5894078A (en) * | 1996-02-26 | 1999-04-13 | Advanced Bioconcept, Inc. | Transgenic mouse expressing C-100 app |
-
2008
- 2008-06-09 US US12/452,198 patent/US20100130567A1/en not_active Abandoned
- 2008-06-09 EP EP08765314.3A patent/EP2174666B1/en active Active
- 2008-06-09 WO PCT/JP2008/060513 patent/WO2009001661A1/ja active Application Filing
- 2008-06-09 JP JP2009520426A patent/JP5311413B2/ja active Active
- 2008-06-09 ES ES08765314.3T patent/ES2446296T3/es active Active
- 2008-06-12 TW TW097121836A patent/TWI441634B/zh active
-
2012
- 2012-06-06 US US13/489,580 patent/US20120302614A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0578328A (ja) * | 1991-02-21 | 1993-03-30 | Sankyo Co Ltd | ビフエニルメチルイミダゾール誘導体 |
WO2007112288A2 (en) * | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
Non-Patent Citations (11)
Title |
---|
GARD P.R.: "Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression", EXPERT OPIN. THER. TARGETS, vol. 8, no. 1, 2004, pages 7 - 14, XP009078785 * |
GIROUARD H. ET AL.: "Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals", ARTERIOSCLER. THROMB. VASC. BIOL., vol. 26, no. 4, 2006, pages 826 - 832, XP008128002 * |
HOSOMI N. ET AL.: "Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia", NEUROSCIENCE, vol. 134, no. 1, 2005, pages 225 - 231, XP004971926 * |
IWAI M. ET AL.: "The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage", J. HYPERTENS., vol. 24, no. 10, 2006, pages 2023 - 2031, XP008128005 * |
KANA TSUKUDA; MASAKI MOGI; MASARU IWAI; MASATSUGU HORIUCHI, DEPARTMENT OF MOLECULAR CARDIOVASCULAR BIOLOGY AND PHARMACOLOGY |
MOGI M. ET AL.: "Inhibition of cognitive decline in mice fed ad high-salt and cholesterol diet by the angiotensin receptor blockade, olmesartan", NEUROPHARMACOLOGY, vol. 53, no. 8, 2007, pages 899 - 905, XP022358182 * |
ROSENDORFF C.: "Certain anti-hypertensive agents reduce beta-amyloid neuropathology and improve cognition in a mouse model of Alzheimer's disease", CIRCULATION, vol. 114, no. 18, 2006, pages - 129, XP008128003 * |
See also references of EP2174666A4 * |
TRENKWALDER P.: "Potential for antihypertensive treatment with an AT(1)-receptor blocker to reduce dementia in the elderly", J. HUM. HYPERTENS., vol. 16, no. SUPPL. 3, 2002, pages S71 - S75, XP008128004 * |
TSUKUDA K. ET AL.: "Koshokuen.Koshiboshoku Fuka de Mitomerareta Ninchi Kino no Teika ni Taisuru Olmesartan to Azelnidipine no Koka", JAPANESE JOURNAL OF GERIATRICS, vol. 44, 20 May 2007 (2007-05-20), pages 129, XP008127986 * |
WANG J. ET AL.: "Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease", J. CLIN. INVEST., vol. 117, no. 11, 2007, pages 3393 - 3402, XP002589379 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101062907B1 (ko) | 2009-10-20 | 2011-09-06 | 주식회사 씨티씨바이오 | 올메사탄 실렉세틸을 포함하는 고혈압 치료용 약학 조성물 |
KR101062908B1 (ko) | 2009-10-27 | 2011-09-06 | 주식회사 씨티씨바이오 | 올메사탄 유도체를 포함하는 고혈압 치료용 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
TW200901984A (en) | 2009-01-16 |
US20100130567A1 (en) | 2010-05-27 |
JP5311413B2 (ja) | 2013-10-09 |
EP2174666A4 (en) | 2010-07-21 |
US20120302614A1 (en) | 2012-11-29 |
TWI441634B (zh) | 2014-06-21 |
JPWO2009001661A1 (ja) | 2010-08-26 |
EP2174666B1 (en) | 2013-12-18 |
ES2446296T3 (es) | 2014-03-07 |
EP2174666A1 (en) | 2010-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006096439A3 (en) | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases | |
WO2007087431A3 (en) | Sublingual fentanyl spray | |
WO2005002515A3 (en) | Delivery of therapeutic compounds to the brain and other tissues | |
WO2005079756A3 (en) | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions | |
WO2009017837A3 (en) | Sublingual fentanyl spray | |
IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
WO2006095029A3 (en) | Di-polymer protein conjugates and processes for their preparation | |
MY144857A (en) | Phamaceutical composition comprising amlodipine and losartan | |
WO2009041663A1 (ja) | 皮膚疾患の予防及び/または治療剤 | |
WO2009061431A3 (en) | Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor | |
WO2007127333A3 (en) | Compositions for the treatment and prevention of eyelid swelling | |
WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
EP2196206B8 (en) | Remedy for relieving skin troubles comprising morphinan derivative or pharmacologically acceptable acid addition salt thereof as the active ingredient | |
WO2007092469A3 (en) | Combination of organic compounds | |
WO2009109654A8 (en) | 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1 | |
WO2007135426A3 (en) | Treatment of neurodegeneratives diseases | |
WO2006035282A3 (en) | Muscarinic receptor antagonists | |
WO2007006732A8 (en) | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) | |
WO2005092062A3 (en) | Compounds for neurodegenerative disorders | |
WO2007126898A8 (en) | Use of ladostigil for the treatment of schizophrenia | |
EP1741430A4 (en) | REMEDY FOR PSYCHO NEUROSIS DISEASES | |
WO2008004100A3 (en) | Therapeutic compounds | |
WO2006002846A3 (en) | New analogs of nitrobenzylthioinosine | |
WO2009001661A1 (ja) | アルツハイマー病の予防又は治療のための医薬 | |
WO2007130890A3 (en) | Cyclopentane-derivatives and their use as ocular hypotensive agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08765314 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009520426 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12452198 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008765314 Country of ref document: EP |